Artificial-intelligence-guided autophagy modulation and nanomedicine design for precision photodynamic cancer therapy

Donya Esmaeilpour1, Saeid Ghavami2, Ali Zarrabi3

  • 1Center for Nanotechnology in Drug Delivery, School of Pharmacy, Shiraz University of Medical Science, Shiraz 71345-1583, Iran.

Drug Discovery Today
|March 7, 2026
PubMed

Insights

This review explores using nanomedicine to enhance photodynamic therapy (PDT) for cancer treatment by improving drug delivery and targeting. Artificial intelligence aids in personalizing these advanced PDT strategies to overcome treatment resistance.

Area of Science:

  • Oncology
  • Nanomedicine
  • Photodynamic Therapy (PDT)
  • Artificial Intelligence (AI)

Background:

  • Cancer is a leading global cause of death, with current treatments facing limitations like toxicity, resistance, and lack of tumor selectivity.
  • Photodynamic therapy (PDT) provides controlled cancer cell killing but is hindered by poor photosensitizer delivery, tumor variability, and autophagy's complex role.
  • Autophagy, a cellular process, can promote or inhibit cancer progression and treatment efficacy, necessitating its modulation in therapeutic strategies.

Purpose of the Study:

  • To review advancements in engineering nanomedicine for targeted and stimuli-responsive photodynamic therapy (PDT).
  • To discuss strategies for modulating autophagic flux to overcome PDT resistance in cancer.
  • To highlight the role of artificial intelligence (AI) in personalizing autophagy-informed PDT.

Main Methods:

  • Engineering nanocarriers for enhanced photosensitizer delivery and targeted accumulation in tumors.
  • Developing stimuli-responsive nanomedicines that activate PDT upon specific triggers.
  • Investigating methods to modulate autophagic flux, either inhibiting or promoting it, to enhance PDT efficacy.
  • Utilizing AI, including machine learning and deep learning, to analyze multi-omics and imaging data for personalized treatment planning.

Main Results:

  • Nanomedicine offers improved control over photosensitizer delivery and activation for spatiotemporally controlled PDT.
  • Modulating autophagy can re-sensitize resistant tumors to PDT, improving therapeutic outcomes.
  • AI integration enables the analysis of complex biological data to guide nanocarrier design and treatment personalization.

Conclusions:

  • Nanomedicine-based, targeted, and stimuli-responsive PDT holds significant promise for improving cancer treatment efficacy.
  • Combining nanomedicine with autophagy modulation and AI-driven personalization can overcome key challenges in current PDT.
  • Future directions involve integrating multi-modal data for precise, individualized cancer therapy strategies.